• In late June 2026, Johnson & Johnson presented new data on its FcRn blocker IMAAVY (nipocalimab-aahu) at the European Academy of Neurology Congress, highlighting benefits across early-stage and lower-symptom generalized myasthenia gravis patients, infection periods, and outlining a PETUNIA registry to track pregnancy-related safety outcomes.
• The breadth of these post‑hoc analyses and real‑world evidence plans suggests Johnson & Johnson is working to entrench IMAAVY across multiple clinically sensitive stages of gMG care, which could be important for how physicians position the drug within existing treatment algorithms.
• We’ll now assess how this expanded IMAAVY evidence package, especially the PETUNIA pregnancy safety study, fits into Johnson & Johnson’s broader investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson, you need to be comfortable with a mature healthcare company whose case rests on a broad drug and device portfolio, steady (but not rapid) growth, and disciplined capital returns. The IMAAVY data in generalized myasthenia gravis reinforce J&J’s immunology depth, but they do not change the fact that, in the near term, oncology execution and managing talc and other legal exposures remain the key swing factors for the stock.

Among recent announcements, the European momentum for TECVAYLI and TALVEY in multiple myeloma looks most connected to IMAAVY’s story. Together, they show J&J leaning on high-value specialty franchises, where strong clinical packages in complex diseases matter for physician adoption and pricing power. For shareholders, the near term catalyst remains how well these oncology and immunology launches offset patent pressure and tariffs while J&J prepares to separate its orthopedics business.

Yet even as new data like IMAAVY’s arrive, investors should still be watching the ongoing talc litigation risk and its potential impact on...

Johnson & Johnson's narrative projects $116.6 billion revenue and $26.9 billion earnings by 2029. This requires 6.6% yearly revenue growth and a $5.9 billion earnings increase from $21.0 billion today.

Uncover how Johnson & Johnson's forecasts yield a $252.87 fair value, in line with its current price.

Exploring Other Perspectives

Compared with the baseline view, the most pessimistic analysts assume revenue only reaches about US$109.9 billion and earnings about US$21.9 billion by 2029, so if they are right, even strong IMAAVY data might not fully counter the oncology and MedTech worries they highlight, and you should recognize that reasonable people can look at the same J&J pipeline and reach very different conclusions about its upside.

Explore 7 other fair value estimates on Johnson & Johnson - why the stock might be worth 16% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

No Opportunity In Johnson & Johnson?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 41 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.